Results 71 to 80 of about 492 (136)

The Real‐World Analysis of Adverse Events With Two Types of Single‐Inhaler Triple Therapy: A VigiAccess Database Study

Journal of Clinical Pharmacy and Therapeutics, Volume 2025, Issue 1, 2025.
Background The advent of single‐inhaler triple therapies (SITTs), including fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FOR/GLY), has expanded treatment options for chronic obstructive pulmonary disease (COPD).
Baiquan Zhang, Jiayu Bai, Lu Zhou, Hongda Liu   +3 more
wiley   +1 more source

Thyroid and renal tumors in patients treated with long-term lithium: case series from a lithium clinic, review of the literature and international pharmacovigilance reports

International Journal of Bipolar Disorders, 2018
Background Cancer had never been considered as a relevant problem in patients treated with lithium until 2015, when a document published by the European Medicine Agency concluded that long-term use of lithium might induce renal tumors. A few months later,
Luca Ambrosiani, Claudia Pisanu, Arianna Deidda, Caterina Chillotti, Maria Erminia Stochino, Alberto Bocchetta   +5 more
doaj   +1 more source

Real‐World Data Analysis of Vascular and Lymphatic Adverse Events Associated With Antitumor Angiogenesis Drugs: A WHO‐VigiAccess Study

Journal of Clinical Pharmacy and Therapeutics, Volume 2025, Issue 1, 2025.
Antiangiogenic therapy plays a critical role in cancer treatment. This study analyzed vascular and lymphatic adverse events linked to four FDA‐approved agents—aflibercept, bevacizumab, olaratumab, and ramucirumab—using WHO‐VigiAccess data. Disproportionality analysis (ROR and PRR) identified drug‐specific risks, focusing on hypertension, hemorrhage ...
Yue Zu, Lingling Dai, Peng Meng, Samuel Silvestre   +3 more
wiley   +1 more source

Annual distribution of AE reports for TXA in VigiAccess.

Annual distribution of AE reports for TXA in VigiAccess.
Jing Feng (177843), Chiwei Guo (22569722), Shujuan Zhao (6317975)   +2 more
core   +1 more source

Table1_Characteristic analysis of adverse reactions of five anti-TNFɑ agents: a descriptive analysis from WHO-VigiAccess.XLSX

, 2023
Introduction: Tumor necrosis factor (TNF) inhibitors (adalimumab, infliximab, etanercept, golimumab, and certolizumab pegol) have revolutionized the treatment of severe immune-mediated inflammatory diseases, including rheumatoid arthritis, Crohn’s ...
Ruxu You, Hongbo Zhou (117916), Hongbo Zhou, Mingming Li (502877), Yuyong Su (16638279), Mingming Li, Yuyong Su, Shiwei Gong, Ruxu You (2558287), Shiwei Gong (702502)   +9 more
core   +1 more source

Analysis of publicly available adverse events reported for pediatric patients treated with Janus kinase inhibitors

Pediatric Dermatology, Volume 41, Issue 6, Page 1040-1046, November/December 2024.
Abstract Janus kinase inhibitors (JAKi) are drugs that block tyrosine kinases responsible for transducing cytokine signals. The first JAKi was approved by the US Food and Drug Administration (FDA) in 2011 to treat rheumatoid arthritis in adults. A pediatric indication was not approved until 8 years later, for acute graft‐versus‐host disease. Since then,
Sahithi Talasila, Emily Lee, Eric M. Teichner, Elaine C. Siegfried, Stephanie R. Jackson Cullison   +4 more
wiley   +1 more source

Identification of PT signals for TXA using disproportionality analysis in VigiAccess.

Identification of PT signals for TXA using disproportionality analysis in VigiAccess.
Jing Feng (177843), Chiwei Guo (22569722), Shujuan Zhao (6317975)   +2 more
core   +1 more source

Multiple Acyl‐Coenzyme A Dehydrogenase Deficiency Is Associated with Sertraline Use – Is There an Acquired Form?

Annals of Neurology, Volume 96, Issue 4, Page 802-811, October 2024.
Objective Multiple acyl‐coenzyme A dehydrogenase deficiency (MADD) is a disorder of fatty acid oxidation and considered an inborn error of metabolism. In recent years, we have diagnosed an increasing number of patients where, despite extensive investigation, no disease‐causing mutations have been found. We therefore investigated a cohort of consecutive
Sofie Sunebo, Hanna Appelqvist, Bo Häggqvist, Olof Danielsson   +3 more
wiley   +1 more source

Cardiovascular toxicity with CTLA‐4 inhibitors in cancer patients: A meta‐analysis

Cancer Innovation, Volume 3, Issue 3, June 2024.
1. CTLA‐4 inhibitors restore the T cell immune response against tumor cells. Tumors and cardiomyocytes, shared some muscle‐specific antigens, which trigger a cross‐reactivity with T cells. The inhibitors make cardiac cells susceptible to injury. 2. CTLA‐4 inhibitors significantly increased the incidence of all‐grade cardiovascular toxicity and severe ...
Huiyi Liu, Lu Fu, Shuyu Jin, Xingdong Ye, Yanlin Chen, Sijia Pu, Yumei Xue   +6 more
wiley   +1 more source

Rising cases of drug‐induced pulmonary fibrosis: Analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) database, 2000–2022

Pharmacoepidemiology and Drug Safety, Volume 33, Issue 5, May 2024.
Abstract Purpose Pulmonary fibrosis (PF) is a severe, progressive disease, which may be caused by exposure to certain medications. Methods We queried the U.S. FDA Adverse Event Reporting System (FAERS) from 2000 to 2022, using the search terms “pulmonary fibrosis” and “idiopathic pulmonary fibrosis” and excluded reports with patients under the age of ...
Kenneth L. McCall, Kelsey R. Hennig, Zachary T. Abe, Danielle N. Dattler, Karyssa L. Hurd, Sophie L. Portnoy, Zoey J. Zagoria   +6 more
wiley   +1 more source